Cantor Fitzgerald Reiterates Neutral on Merck & Co, Maintains $120 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 71.6%

Neg 0% Neu 71.6% Pos 0%

Cantor Fitzgerald analyst Carter Gould reiterates Merck & Co (NYSE:MRK) with a Neutral and maintains $120 price target.

Comments

No comments yet. Be the first!